Adaptive Biotechnologies exec exercises options, sells shares

Adaptive Biotechnologies President and COO Julie Rubinstein reported an exercise-and-sell transaction pattern in company stock.

Accepted by SEC EDGAR 03/18/2026 - 06:21 PM EDT

Filing Impact

(Neutral)

Filing Sentiment

(Negative)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Adaptive Biotechnologies President and COO Julie Rubinstein reported an exercise-and-sell transaction pattern in company stock. Over three days, she exercised stock options to acquire a total of 44,166 shares of common stock at an exercise price of $6.55 per share.

She then sold 57,180 shares of common stock in open-market transactions at reported prices of $13.41, $13.40, and $13.18 per share, with each sale executed as multiple trades within disclosed price ranges. All transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 18, 2025.

Following these transactions, Rubinstein directly owned 494,920 shares of Adaptive Biotechnologies common stock, indicating she retained a substantial equity position after the option exercises and sales.

Insider Trade Summary 10b5-1

Exercise and sale activity reported; no spread calculated

Exercise and Sale 9 txns

Insider RUBINSTEIN JULIE

Role President and COO

Sold 57,180 shs ($762K)

Approx. gross sale proceeds $762K

Approx. exercise cost $289K

Type	Security	Shares	Price	Value
Exercise	Stock Option (right to buy)	14,722	$0.00	$0.00
Exercise	Common Stock	14,722	$6.55	$96K
Sale	Common Stock	19,060	$13.18	$251K
Exercise	Stock Option (right to buy)	14,722	$0.00	$0.00
Exercise	Common Stock	14,722	$6.55	$96K
Sale	Common Stock	19,060	$13.40	$255K
Exercise	Stock Option (right to buy)	14,722	$0.00	$0.00
Exercise	Common Stock	14,722	$6.55	$96K
Sale	Common Stock	19,060	$13.41	$256K

Holdings After Transaction: Stock Option (right to buy) — 18,661 contracts (Direct); Common Stock — 494,920 shares (Direct)

Footnotes (5)

F1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.
F2. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.26 to $13.80, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F3. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.23 to $13.61, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F4. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.02 to $13.37, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F5. The option is fully vested and exercisable.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Adaptive Biotechnologies (ADPT) report for Julie Rubinstein?

Adaptive Biotechnologies reported that President and COO Julie Rubinstein exercised stock options for 44,166 common shares and sold 57,180 shares in open-market transactions. These trades occurred over three days and were executed under a pre-arranged Rule 10b5-1 trading plan.

How many Adaptive Biotechnologies (ADPT) shares does Julie Rubinstein hold after these Form 4 transactions?

After the reported transactions, Julie Rubinstein directly owned 494,920 shares of Adaptive Biotechnologies common stock. This figure reflects her position following the option exercises and subsequent sales disclosed in the Form 4 filing for March 16–18, 2026.

What prices were involved in Julie Rubinstein’s ADPT stock option exercises and sales?

Julie Rubinstein exercised stock options at an exercise price of $6.55 per share and sold shares at reported prices of $13.41, $13.40, and $13.18. Footnotes state each sale price is a weighted average across multiple trades within specified intraday price ranges.

Were Julie Rubinstein’s ADPT stock sales made under a Rule 10b5-1 plan?

Yes. The Form 4 footnotes state the transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by Julie Rubinstein on November 18, 2025. Such pre-arranged plans schedule trades in advance, helping separate routine liquidity events from discretionary market timing.

How many shares did Julie Rubinstein sell in this Adaptive Biotechnologies (ADPT) Form 4?

Across three open-market sale transactions, Julie Rubinstein sold a total of 57,180 shares of Adaptive Biotechnologies common stock. Each sale involved 19,060 shares on separate days, at weighted average prices in the low-$13 range as detailed in the filing footnotes.

How many stock options did Julie Rubinstein exercise in the latest ADPT Form 4?

Julie Rubinstein exercised stock options covering 44,166 shares of Adaptive Biotechnologies common stock. The options had an exercise price of $6.55 per share and were described as fully vested and exercisable in the accompanying footnote to the Form 4 filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

RUBINSTEIN JULIE

(Last)

(First)

(Middle)

C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION

1165 EASTLAKE AVENUE EAST

(Street)

SEATTLE

WASHINGTON

98109

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Adaptive Biotechnologies Corp [ ADPT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	President and COO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	03/16/2026		M⁽¹⁾		14,722	A	$6.55	522,656	D
Common Stock	03/16/2026		S⁽¹⁾		19,060	D	$13.41⁽²⁾	503,596	D
Common Stock	03/17/2026		M⁽¹⁾		14,722	A	$6.55	518,318	D
Common Stock	03/17/2026		S⁽¹⁾		19,060	D	$13.4⁽³⁾	499,258	D
Common Stock	03/18/2026		M⁽¹⁾		14,722	A	$6.55	513,980	D
Common Stock	03/18/2026		S⁽¹⁾		19,060	D	$13.18⁽⁴⁾	494,920	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (right to buy)	$6.55	03/16/2026		M⁽¹⁾			14,722	⁽⁵⁾	02/07/2028	Common Stock	14,722	$0	48,105	D
Stock Option (right to buy)	$6.55	03/17/2026		M⁽¹⁾			14,722	⁽⁵⁾	02/07/2028	Common Stock	14,722	$0	33,383	D
Stock Option (right to buy)	$6.55	03/18/2026		M⁽¹⁾			14,722	⁽⁵⁾	02/07/2028	Common Stock	14,722	$0	18,661	D

Explanation of Responses:

1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

2. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.26 to $13.80, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

3. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.23 to $13.61, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

4. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.02 to $13.37, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

5. The option is fully vested and exercisable.

	/s/ Julie Rubinstein by Kyle Piskel, Attorney-in-Fact	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR